Formulation Development White Papers & Articles

1. Streamline Your Pathway To IND With A Rapid Tox Approach 6/26/2025

   With tox material in hand as soon as possible, antibody-derived drug developers can conduct their tox studies earlier, facilitating a timely IND submission and speeding up pathways to patients.

2. Experimental Pain Models — SNL Model Of Neuropathic Pain 6/20/2025

   Explore how a validated Spinal Nerve Ligation (SNL) model enables effective preclinical evaluation of novel analgesics for neuropathic pain.

3. Quicker Development Using Cell Line Integration, End-To-End Support 6/19/2025

   Despite challenges with mammalian host cell line diversity, Lonza's mitigation strategies drive efficiency and reproducibility, maximizing cell growth and product quality.

4. Experimental CCI — Induced Neuropathic Pain Model 6/18/2025

   Advance neuropathic pain research and therapeutic development with the Chronic Constriction Injury (CCI)-induced neuropathic pain model to uncover mechanisms and evaluate promising candidates.

5. Manufacturing CAR T Cell Therapies: Challenges, Insights And Solutions 6/16/2025

   Manufacturing patient-specific cell therapies is a complex, multi-step process. Addressing key hurdles in production time, scalability, and cost is crucial to making these vital treatments more accessible.

6. Preclinical Evaluation Of Vaccines And Antivirals In RSV Challenge Rodent Models 6/10/2025

   Here, we present multiple case studies utilizing clinically relevant mouse and rat models to evaluate key characteristics of potential RSV therapeutics.

7. Preclinical Evaluation Of New Antifibrotics In NASH-Induced Fibrosis Models 6/10/2025

   Accelerate the development of antifibrotic therapies through our clinically relevant models, deep scientific expertise, and proven preclinical capabilities in this area of unmet medical need.

8. Preclinical Evaluation Of Antifibrotics In COVID-Induced Fibrosis Model 6/10/2025

   Advancing the development of effective antifibrotic therapies requires urgent investment in clinically relevant, IND-enabling preclinical models to address the growing burden of fibrotic diseases.

9. Preclinical Evaluation Of Vaccines And Antivirals In RSV Challenge SCID Mouse Models 6/10/2025

   Advance your RSV therapeutic pipeline with trusted, IND-enabling preclinical services that deliver clinically relevant data through optimized study designs and validated rodent models.

10. Preclinical Evaluation Of RSV Vaccines And Antivirals In BALB/c Mice 6/10/2025

    Accelerate your RSV therapeutic development with clinically relevant preclinical models and expert IND-enabling services that deliver the data needed to advance confidently toward clinical trials.